Immunization, Hib3 in Panama
Panama: Immunization, Hib3 was 72.0% in 2024. ▼ Falling
Immunization, Hib3 in Panama, 2001–2024
Source: WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/). Measured in % of children ages 12-23 months.
Analysis
In 2024, immunization, hib3 in Panama stood at 72.0%.
The figure is up 1.4% on the previous year and down 10.0% over ten years.
Over the whole period, immunization, hib3 in Panama peaked at 99.0% in 2001 and was at its lowest, 71.0%, in 2023.
That places Panama 160th out of 191 countries with data for 2024, putting it in the bottom quarter.
The long-run direction has been consistently falling across the 24 years of available data.
Immunization, Hib3 in Panama, year by year
| Year | % of children ages 12-23 months | Change |
|---|---|---|
| 2001 | 99.0% | — |
| 2002 | 99.0% | +0.0% |
| 2003 | 98.0% | -1.0% |
| 2004 | 95.0% | -3.1% |
| 2005 | 92.0% | -3.2% |
| 2006 | 88.0% | -4.3% |
| 2007 | 85.0% | -3.4% |
| 2008 | 86.0% | +1.2% |
| 2009 | 85.0% | -1.2% |
| 2010 | 94.0% | +10.6% |
| 2011 | 87.0% | -7.4% |
| 2012 | 85.0% | -2.3% |
| 2013 | 80.0% | -5.9% |
| 2014 | 80.0% | +0.0% |
| 2015 | 73.0% | -8.8% |
| 2016 | 86.0% | +17.8% |
| 2017 | 81.0% | -5.8% |
| 2018 | 88.0% | +8.6% |
| 2019 | 88.0% | +0.0% |
| 2020 | 74.0% | -15.9% |
| 2021 | 87.0% | +17.6% |
| 2022 | 82.0% | -5.7% |
| 2023 | 71.0% | -13.4% |
| 2024 | 72.0% | +1.4% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 91.9% | 85.0% | 99.0% | 9 |
| 2010s | 84.2% | 73.0% | 94.0% | 10 |
| 2020s | 77.2% | 71.0% | 87.0% | 5 |
Countries ranked near Panama
- 157 Ethiopia 73.0% compare
- 157 South Sudan 73.0% compare
- 157 Syrian Arab Republic 73.0% compare
- 160 Marshall Islands 72.0% compare
- 162 Micronesia, Federated States of 71.0% compare
- 162 Myanmar 71.0% compare
- 162 Philippines 71.0% compare
- 162 Vanuatu 71.0% compare
More health data for Panama
- Un projection of annual infant deaths, annual growth rate -1.94 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 0.5994 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,074 deaths per 1,000 people (2090)
- Number of infants who die before age 1 101 deaths (2100)
- Population ages 30-34, female, annual growth rate 0.7653 % change on previous year (2025)
- Population ages 30-34, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 30-34, female, per capita 0.0366 units per person (2025)
- Population ages 30-34, male, annual growth rate 0.8167 % change on previous year (2025)
- Population ages 30-34, male, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 30-34, male, per capita 0.0372 units per person (2025)
Frequently asked questions
- What is immunization, hib3 in Panama?
- Immunization, hib3 in Panama was 72.0% in 2024, according to WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/).
- What is the highest immunization, hib3 recorded in Panama?
- The highest recorded value was 99.0% in 2001.
- What is the lowest immunization, hib3 recorded in Panama?
- The lowest recorded value was 71.0% in 2023.
- How does Panama rank for immunization, hib3?
- Panama ranks 160th out of 191 countries with data for 2024.
- Is immunization, hib3 rising or falling in Panama?
- Over the last ten years it is down 10.0%. The long-run trend across the full record is falling.
- Where does this Panama data come from?
- The figures come from WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/), published as part of Immunization, Hib3 (% of children ages 12-23 months). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 24 observations, free to reuse under CC BY 4.0 (World Bank Open Data).
About this data
Child immunization, Hib3, measures the percentage of children ages 12-23 months who received Hib3 vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized against Hib3 after receiving three doses of Haemophilus influenzae type b vaccine.